Important upcoming anticipated events for MoonLake: Q2-2024: Initiation of the Phase 3 VELA program in HS; Q2-2024: End-of-Phase 2 meetings with the FDA and EMA for PsA; 2H-2024: Initiation of the Phase 3 program in PsA; 2H-2024: Initiation of additional studies as announced for dermatology and rheumatology indications
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
- 3 Best Stocks to Buy Now, 4/29/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 4/24/2024, According to Top Analysts
- MoonLake Immunotherapeutics enters three-year partnership with Komodo Health
- Estee Lauder upgraded, Petco downgraded: Wall Street’s top analyst calls
